info@aurevixpeptides.com
EspañolRead references
Illustrative vial: Tesamorelin + IpamorelinTesamorelin + Ipamorelin

Illustrative presentation

INFORMATIONAL REFERENCE

Tesamorelin (10mg) + Ipamorelin (5mg)

This combination brings together Tesamorelin, Ipamorelin. Explore each component’s research focus below, followed by the evidence for the combination.

Research focus & potential applications

Tesamorelin

Tesamorelin stimulates the GHRH pathway. Human studies in HIV-associated abdominal fat accumulation have measured reduced visceral fat; that specific finding should not be confused with general body-weight loss.

Ipamorelin

Ipamorelin is investigated for ghrelin-receptor activity, growth-hormone release and gastrointestinal function. These are distinct research areas; the postoperative trial discussed below did not establish its primary recovery benefit.

What the research shows

Explore the selected studies, their findings and their limits.

Tesamorelin

Read the findings & sourcesHuman study discussed

A randomized 26-week trial in 412 people with HIV-associated abdominal fat accumulation reported a 15.2% reduction in visceral fat with tesamorelin, versus a 5.0% increase with placebo. This was an imaging measure of internal abdominal fat, not a 15.2% reduction in body weight. IGF-1 also increased; the findings do not establish a general weight-loss or anti-aging effect in healthy adults.

Ipamorelin

Read the findings & sourcesHuman study discussed

Ipamorelin has been investigated as a growth-hormone secretagogue and for bowel recovery after surgery. In a randomized postoperative study, the primary comparison for recovery of gastrointestinal function was not statistically significant. A proposed mechanism or hormone response therefore should not be presented as demonstrated recovery, sleep or body-composition benefit.

Evidence for the combination

The sources above examine individual constituents or related molecules. They do not test this exact combination. A combined effect, improved recovery or greater safety cannot be inferred by adding the individual findings together.

For more information, contact info@aurevixpeptides.com.

Editorial review: September 23, 2026